DOI: http://dx.doi.org/10.18203/2349-3259.ijct20151236

Funding of clinical trials in Brazil for the development of new drugs: who are the sponsors?

Ricardo Eccard da Silva, Angélica Amorim Amato, Maria Rita Carvalho Garbi Novaes

Abstract


Background: A low rate of investment in science it is directly impacts the technological independence and capacity in health care costs. Knowledge of funding sources is critical to understand the problem and formulates hypotheses for future studies.

Methods: Two databases were used: the System for Control of Clinical Research (SCCR) from the Brazilian Health Surveillance Agency (Anvisa), and the International Clinical Trials Registry Platform (ICTRP).  

Results: From 2009 to 2012, 77% of the clinical trials approved by Anvisa were sponsored by transnational pharmaceutical industry. On the other hand, the national pharmaceutical industry sponsored 8% of the trials over the same period. The most frequent sponsor of clinical trials involving drugs registered in the ICTRP from 2011 to 2012 was the transnational pharmaceutical industry (43%). Among the trials with national sponsors, are those involving neglected diseases such as chronic hepatitis C (ICD X B18.2), cutaneous leishmaniasis (ICD X B55.1) and yellow fever (ICD X A95), which were all sponsored by national governmental foundations. None of the active pharmaceutical ingredients studied by the transnational pharmaceutical industry or the transnational biopharmaceutical company were in the national list of essential medicines. On the other hand, 83% and 66.6% of the active pharmaceutical ingredients studied by national private universities and the international governmental agency, respectively, are in the national list of essential medicines.  

Conclusions: The national pharmaceutical industry and government still invests little in Research and Development (R&D) activities, when compared with transnational industries. This affects directly its technological and innovation ability.


Keywords


Clinical trials, Sponsor, Research funding, Drugs

Full Text:

PDF

References


Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Revi Drug Discovery. 2010;9:203-214.

Berndt ER, Cockburn I, Thiers FA. The globalization of clinical trials for new medicines into emerging economies: where are they going and why? Maastricht, the Netherlands: UNU-MERIT Conference, Micro Evidence on Innovation in Developing Countries; 2007.

Capanema LXL. A indústria farmacêutica brasileira e a atuação do BNDES. BNDES Setorial, Rio de Janeiro. 2006 Mar;23:193-216.

Wright BD, Merrill SA. Industry-funded academic inventions boost innovation. Nature. 2014;507:297-9.

Chaimovich, HERNAN e Melcop, Paula D. Notas preliminares sobre financiamento à pesquisa no Brasil. REVISTA USP, São Paulo. 2007 março/maio;73:6-23.

National Institute of Health (NIH). Age filters, 2014. Available at: http://www.ncbi.nlm.nih.gov/books/NBK3827/. Accessed 16 April 2014.

Academia Brasileira de Ciências. Ciência e tecnologia para o desenvolvimento nacional. Estudos estratégicos. Rio de Janeiro: Doenças negligenciadas / Wanderley de Souza, coordenador; 2010: 56.

World Health Organization. Promoting safety of medicines for children. Library cataloguing in publication data. Geneva: WHO; 2007

CenterWatch. FDA approved drugs by therapeutic area, 2014. Available at: http://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/15/pediatrics-neonatology. Accessed 04 February 2014.

Ledford H. Disease research: rare insights. Scientists who specialize in uncommon diseases can find a research focus with a purpose. Nature. 2014;505:443-5.

Brasil. Ministério da Saúde. Sistema de Informações Hospitalares do Sistema Único de Saúde, 2009. Available at: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?idb2010/d13.def Accessed 04 February 2014.

Baker, Dean. Financing drug research: what are the issues? Industry Studies Association. Working Papers Series. Washington, DC: Center for Economic and Policy Research; 2009.

Paula AP, Giozza SP, Pereira MZ, Boaventura PS, Santos LM, Sachetti CG, et al. Clinical investigations for SUS, the Brazilian public health system. Sao Paulo Med J. 2012;30(3):179-86.

Ministério da Saúde. Departamento de Ciência e Tecnologia, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Doenças negligenciadas: estratégias do Ministério da Saúde. Rev Saúde Pública. 2010;44(1):200-2.

Portal Brasil. Busca por financiamento em projetos de pesquisa e inovação superam expectativas, 2013. Available at: http://www.brasil.gov.br/saude/2013/10/busca-por-financiamento-em-projetos-de-pesquisa-e-inovacao-superam-expectativas. Accessed 04 March 2014.

Filho PLP, Pieroni JP, Antunes A, Bomtempo JV. O desafio do financiamento à inovação farmacêutica no Brasil: a experiência do BNDES Profarma. Revista do BNDES. 2012;37:67-90.

Calderan LL, e Oliveira LG. Centro de Estudos Avançados de Governo e de Administração Pública - CEAG. A inovação e a interação Universidade-Empresa: uma revisão teórica. Brasília: Série textos de discussão CEAG/UnB; 2013: 1-39.

Wright BD, Merrill SA. Industry-funded academic inventions boost innovation. Nature. 2014;507;297-9.

Brasil. Lei nᵒ 10.168 de 29 de dezembro de, 2000. Institui contribuição de intervenção de domínio econômico destinada a financiar o Programa de Estímulo à interação Universidade-Empresa para o Apoio à inovação e dá outras providências. Available at: http://www.planalto.gov.br/ccivil_03/leis/L10168.htm.

Viana ALD, Iozzi FL, Albuquerque MV, Bousquat A. Saúde, desenvolvimento e inovação tecnológica: nova perspectiva de abordagem e de investigação. Lua Nova. 2011;83:41-77.

Quental, Cristiane Machado; FILHO, Sérgio Salles. Ensaios Clínicos em Medicamentos: capacitação nacional para apoio à inovação farmacêutica. In: BUSS, Paulo Marchiori, eds. Medicamentos no Brasil: Inovação & Acesso. Rio de Janeiro: FIOCRUZ; 2008: 129-141.

Projeto BRICS. Estudo comparativo dos sistemas de inovação no Brasil, Rússia, Índia, China e África do Sul. Redesist. Rio de Janeiro: Universidade Federal; 2007.